Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment

201667 citationsJournal Articlegold Open Access

Authors

Andrew Hill · University of Liverpool

Dzintars Gotham · Imperial College London

Joseph Fortunak · Howard University

Jonathan Meldrum · University College London

Isabelle Erbacher · Imperial College London

Manuel de Mora Martín · Imperial College London

Haitham Shoman ·

Abstract

Mass generic production of several TKIs could achieve treatment prices in the range of $128-$4020 per person-year, versus current US prices of $75161-$139,138. Generic TKIs could allow significant savings and scaling-up of treatment globally, for over 1 million eligible patients.

Topics & Keywords

Chronic Lymphocytic Leukemia Research Chronic Myeloid Leukemia Treatments HIV/AIDS drug development and treatment

Publication Details

Published in: BMJ Open

Volume 6, Issue 1, pp. e009586-e009586

DOI: 10.1136/bmjopen-2015-009586

Field-Weighted Citation Impact: 6.25

Command Palette

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment

Authors

Abstract

Topics & Keywords

Publication Details